Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed medicines -- the only ones in the world -- that target the underlying causes of a rare disease called cystic fibrosis (CF).
So far, Vertex's monopoly has remained intact despite many of its peers trying to break into this space. But could that change soon? Sionna Therapeutics, a privately held biotech, certainly hopes so.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€396.40
1.080%
With 45 Buy predictions and not a single Sell prediction Vertex Pharmaceuticals Inc. is an absolute favorite of our community.
As a result the target price of 489 € shows a positive potential of 23.36% compared to the current price of 396.4 € for Vertex Pharmaceuticals Inc..
